Nuvation Bio (NYSE:NUVB) Shares Gap Up – Here’s Why

Posted by George Bondi on Jun 9th, 2026

Nuvation Bio Inc. (NYSE:NUVB – Get Free Report)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $4.80, but opened at $5.08. Nuvation Bio shares last traded at $5.01, with a volume of 2,608,534 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on NUVB. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Nuvation Bio in a report on Tuesday, May 5th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a report on Tuesday, May 5th. Zacks Research downgraded shares of Nuvation Bio from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Nuvation Bio in a report on Tuesday, May 5th. Finally, UBS Group lowered their target price on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Nuvation Bio currently has an average rating of “Moderate Buy” and an average price target of $12.50.

View Our Latest Research Report on Nuvation Bio

Nuvation Bio Trading Down 1.4%

The company has a quick ratio of 7.24, a current ratio of 7.44 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $4.69 and a 200 day simple moving average of $5.94. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -10.97 and a beta of 1.52.

Nuvation Bio (NYSE:NUVB – Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. Nuvation Bio had a negative return on equity of 44.10% and a negative net margin of 102.06%.The company had revenue of $83.23 million during the quarter, compared to the consensus estimate of $66.22 million. On average, equities analysts anticipate that Nuvation Bio Inc. will post -0.39 EPS for the current fiscal year.

Insiders Place Their Bets

In other Nuvation Bio news, insider Kerry Wentworth sold 36,750 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $5.01, for a total value of $184,117.50. Following the completion of the sale, the insider owned 53,000 shares of the company’s stock, valued at approximately $265,530. This trade represents a 40.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dongfang Liu sold 50,000 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $5.02, for a total value of $251,000.00. Following the completion of the sale, the insider directly owned 18,000 shares of the company’s stock, valued at approximately $90,360. This trade represents a 73.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 286,750 shares of company stock valued at $1,339,118. 30.11% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC raised its stake in shares of Nuvation Bio by 9.8% during the 4th quarter. HighTower Advisors LLC now owns 22,457 shares of the company’s stock worth $201,000 after buying an additional 2,007 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of Nuvation Bio by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after buying an additional 2,597 shares during the last quarter. Russell Investments Group Ltd. raised its position in Nuvation Bio by 17.7% during the fourth quarter. Russell Investments Group Ltd. now owns 24,456 shares of the company’s stock worth $219,000 after acquiring an additional 3,681 shares during the last quarter. Meridian Wealth Management LLC raised its position in Nuvation Bio by 3.8% during the fourth quarter. Meridian Wealth Management LLC now owns 113,565 shares of the company’s stock worth $1,018,000 after acquiring an additional 4,200 shares during the last quarter. Finally, Mackenzie Financial Corp raised its position in Nuvation Bio by 38.8% during the third quarter. Mackenzie Financial Corp now owns 15,746 shares of the company’s stock worth $58,000 after acquiring an additional 4,400 shares during the last quarter. Institutional investors and hedge funds own 61.67% of the company’s stock.

About Nuvation Bio

(Get Free Report)

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.